Parahuleva Nikoleta, Mihaylova Anna, Harizanova Stanislava, Merdzhanova Yana, Koleva Mariya, Madzharov Vasil, Strikova Gergana, Uchikova Ekaterina
Department of Obstetrics and Gynecology, Medical Faculty, Medical University of Plovdiv, 4002 Plovdiv, Bulgaria.
Department of Health Care Management, Faculty of Public Health, Medical University of Plovdiv, 4002 Plovdiv, Bulgaria.
Healthcare (Basel). 2025 Apr 11;13(8):884. doi: 10.3390/healthcare13080884.
: Among the therapeutic options available for managing PCOS, metformin improves insulin sensitivity, reduces androgen levels, and helps restore menstrual regularity and ovulation. While primarily used for its metabolic effects, metformin therapy may also influence reproductive parameters, including AMH levels, which are pivotal in improving ovarian function and predicting therapeutic outcomes in PCOS. The aim of this study was to search the scientific literature and analyze the correlation between AMH levels and metformin hydrochloride therapy in women with PCOS and IR. : A systematic review of the scientific literature was conducted using the following keywords: polycystic ovarian syndrome, anti-Mullerian hormone, insulin resistance, metformin, treatment, biomarker, and metabolic syndrome. This review was aimed at investigating the potential of AMH as a biomarker of the effectiveness of metformin therapy in patients with PCOS and IR. : Metformin treatment in PCOS patients has shown significant reductions in serum AMH levels with prolonged therapy. As an insulin sensitizer, metformin improves insulin sensitivity, reduces hyperinsulinemia, and suppresses hyperandrogenism. This process inhibits the growth of antral follicles, which is reflected in decreased AMH levels. : Reductions in AMH levels and improvements in insulin sensitivity can serve as indicators of treatment efficacy and enhancements in reproductive function for these patients. AMH could be considered a prognostic marker for evaluating the effectiveness of metformin therapy. A decrease in AMH levels following treatment may indicate improved ovarian function and a reduction in polycystic morphology. However, further research is necessary to confirm these findings and to determine the optimal dosages and duration of treatment.
在多囊卵巢综合征（PCOS）的现有治疗方案中，二甲双胍可提高胰岛素敏感性、降低雄激素水平，并有助于恢复月经规律和排卵。虽然二甲双胍主要因其代谢作用而被使用，但它也可能影响生殖参数，包括抗苗勒管激素（AMH）水平，而AMH水平对于改善PCOS患者的卵巢功能和预测治疗效果至关重要。本研究的目的是检索科学文献，并分析PCOS合并胰岛素抵抗（IR）女性的AMH水平与盐酸二甲双胍治疗之间的相关性。
多囊卵巢综合征、抗苗勒管激素、胰岛素抵抗、二甲双胍、治疗、生物标志物和代谢综合征。本综述旨在研究AMH作为PCOS合并IR患者二甲双胍治疗有效性生物标志物的潜力。
PCOS患者长期接受二甲双胍治疗后，血清AMH水平显著降低。作为一种胰岛素增敏剂，二甲双胍可提高胰岛素敏感性、降低高胰岛素血症并抑制高雄激素血症。这一过程抑制了窦卵泡的生长，反映为AMH水平降低。
AMH水平降低和胰岛素敏感性改善可作为这些患者治疗效果和生殖功能增强的指标。AMH可被视为评估二甲双胍治疗有效性的预后标志物。治疗后AMH水平降低可能表明卵巢功能改善和多囊形态减少。然而，需要进一步研究来证实这些发现，并确定最佳治疗剂量和疗程。
